Safety of Interleukin Inhibitors in Patients with Plaque Psoriasis and Neoplasm: A Retrospective Study from Two Referral Centers

Luigi Gargiulo^{1

2}, Luciano Ibba^{3

4}, Mario Valenti^{1

2}, Diego Orsini⁵, Antonio Cristaudo⁵, Pasquale Frascione⁶, Antonio Costanzo^{1

2}, Alessandra Narcisi¹

Affiliations

¹ Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
² Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy.
³ Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. luciano.ibba@humanitas.it.
⁴ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy. luciano.ibba@humanitas.it.
⁵ UOC Dermatologia Clinica, Istituto Dermatologico San Gallicano (IRCCS), Rome, Italy.
⁶ UOSD Dermatologia Oncologica, Istituto Dermatologico San Gallicano (IRCCS), Rome, Italy.

Luigi Gargiulo et al. Clin Drug Investig. 2023 Oct.

. 2023 Oct;43(10):807-812.

doi: 10.1007/s40261-023-01306-2. Epub 2023 Sep 16.

Luigi Gargiulo^{1

2}, Luciano Ibba^{3

4}, Mario Valenti^{1

2}, Diego Orsini⁵, Antonio Cristaudo⁵, Pasquale Frascione⁶, Antonio Costanzo^{1

2}, Alessandra Narcisi¹

¹ Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
² Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy.
³ Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. luciano.ibba@humanitas.it.
⁴ Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy. luciano.ibba@humanitas.it.
⁵ UOC Dermatologia Clinica, Istituto Dermatologico San Gallicano (IRCCS), Rome, Italy.
⁶ UOSD Dermatologia Oncologica, Istituto Dermatologico San Gallicano (IRCCS), Rome, Italy.

No abstract available

Cited by

Clinical features, treatment, and outcomes of anti-PD-L1 induced psoriasis.
Xiao J, Xia Z, Wu Z, Fang M. Xiao J, et al. Invest New Drugs. 2025 Jun;43(3):719-727. doi: 10.1007/s10637-025-01554-3. Epub 2025 Jun 6. Invest New Drugs. 2025. PMID: 40474015
The Intersection of Psoriasis and Neoplasia: Risk Factors, Therapeutic Approaches, and Management Strategies.
Mateescu LA, Savu AP, Mutu CC, Vaida CD, Șerban ED, Bucur Ș, Poenaru E, Nicolescu AC, Constantin MM. Mateescu LA, et al. Cancers (Basel). 2024 Dec 18;16(24):4224. doi: 10.3390/cancers16244224. Cancers (Basel). 2024. PMID: 39766123 Free PMC article. Review.

1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94. https://doi.org/10.1016/S0140-6736(14)61909-7 . - DOI - PubMed
1. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40. https://doi.org/10.1016/j.jaad.2018.06.057 . - DOI - PubMed
1. Gisondi P, Fargnoli MC, Amerio P, Argenziano G, Bardazzi F, Bianchi L, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157(Suppl. 1 to No. 1):1–78. https://doi.org/10.23736/S2784-8671.21.07132-2 . - DOI - PubMed
1. Zagni E, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, et al. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. BMC Health Serv Res. 2021;21(1):924. https://doi.org/10.1186/s12913-021-06866-7 . - DOI - PubMed - PMC
1. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53. https://doi.org/10.1016/j.jaad.2018.06.056 . - DOI - PubMed